StockNews.com Begins Coverage on VolitionRx (NYSE:VNRX)

Investment analysts at StockNews.com began coverage on shares of VolitionRx (NYSE:VNRX) in a research note issued on Thursday. The firm set a “sell” rating on the stock.

A number of other equities research analysts have also issued reports on VNRX. D. Boral Capital reaffirmed a “buy” rating and issued a $5.00 target price on shares of VolitionRx in a research note on Wednesday, January 8th. Benchmark reiterated a “hold” rating on shares of VolitionRx in a report on Friday, November 22nd.

VolitionRx Stock Performance

VNRX stock opened at $0.61 on Thursday. VolitionRx has a 1 year low of $0.43 and a 1 year high of $1.23. The stock’s 50 day moving average price is $0.65 and its 200 day moving average price is $0.66. The firm has a market cap of $56.64 million, a P/E ratio of -1.70 and a beta of 1.20.

Insider Transactions at VolitionRx

In other VolitionRx news, CEO Cameron John Reynolds purchased 139,811 shares of the firm’s stock in a transaction that occurred on Monday, December 9th. The stock was purchased at an average cost of $0.57 per share, with a total value of $79,692.27. Following the transaction, the chief executive officer now owns 2,117,404 shares in the company, valued at approximately $1,206,920.28. This trade represents a 7.07 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Guy Archibald Innes purchased 174,764 shares of the firm’s stock in a transaction that occurred on Monday, December 9th. The shares were acquired at an average cost of $0.57 per share, with a total value of $99,615.48. Following the completion of the transaction, the director now owns 617,085 shares in the company, valued at $351,738.45. This trade represents a 39.51 % increase in their position. The disclosure for this purchase can be found here. Insiders bought a total of 358,266 shares of company stock worth $204,212 in the last ninety days. Insiders own 12.80% of the company’s stock.

Institutional Trading of VolitionRx

An institutional investor recently raised its position in VolitionRx stock. Ground Swell Capital LLC increased its holdings in shares of VolitionRx Limited (NYSE:VNRX) by 78.8% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 45,959 shares of the company’s stock after purchasing an additional 20,249 shares during the period. Ground Swell Capital LLC’s holdings in VolitionRx were worth $28,000 as of its most recent filing with the Securities and Exchange Commission. 8.09% of the stock is owned by hedge funds and other institutional investors.

VolitionRx Company Profile

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes.